Conneqt Health Limited has released a press release.
$0.6 million pharmaceutical trial extension
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Conneqt Health
- SphygmoCor selected for US publicly funded study
- US$1.1 million pharmaceutical contract
- Patent granted in USA
- FDA clearance for Oscar 2 with SphygmoCor inside
- CPT-1 Reimbursement Update
Later from Conneqt Health
- Large national plan to reimburse SphygmoCor test
- FY2016 results
- Leading research team highlights role of SphygmoCor
- AtCor completes share placement
- Positive Novartis drug trial using SphygmoCor XCEL
Follow Conneqt Health into a list and get an email when it puts out news.
Follow Conneqt Health